Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996-2016

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical characterization of delayed alcohol-induced headache: A study of 1,108 participants

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Permanent muscle weakness in hypokalemic periodic paralysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Natalizumab inhibits the migration of systemic immune cells to the CNS and may be beneficial in progressive multiple sclerosis (MS). The objective of the study was to examine the effects of natalizumab in progressive MS.

METHODS: In an open-label phase 2A study, 24 patients with progressive MS were included to receive natalizumab treatment for 60 weeks. Response to natalizumab was assessed in CSF and MRI studies. The primary endpoint was change in CSF osteopontin, a biomarker of intrathecal inflammation, from baseline to week 60.

RESULTS: Seventeen patients completed the study. No new safety issues were encountered. CSF osteopontin decreased by 65 ng/mL (95% confidence interval 34-96 ng/mL; p = 0.0004) from baseline to week 60 in conjunction with decreases in other CSF biomarkers of inflammation, axonal damage, and demyelination. Magnetization transfer ratio increased in both cortical gray and normal-appearing white matter and correlated with decreases in CSF neurofilament light chain.

CONCLUSIONS: Natalizumab treatment of progressive MS reduces intrathecal inflammation and tissue damage, supporting a beneficial effect of natalizumab treatment in progressive MS and suggesting that systemic inflammation contributes to the pathogenesis. Moreover, the study establishes the feasibility of using CSF biomarkers in proof-of-concept trials, allowing a low number of participants and short study duration.

CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with progressive MS, natalizumab reduces biomarkers of intrathecal inflammation.

Original languageEnglish
JournalNeurology
Volume82
Issue number17
Pages (from-to)1499-507
Number of pages9
ISSN0028-3878
DOIs
Publication statusPublished - 29 Apr 2014

    Research areas

  • Adult, Antibodies, Monoclonal, Humanized, Cerebral Cortex, Chemokine CXCL13, Disability Evaluation, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunologic Factors, Magnetic Resonance Imaging, Male, Matrix Metalloproteinase 9, Middle Aged, Multiple Sclerosis, Chronic Progressive, Myelin Basic Protein, Neurofilament Proteins, Osteopontin, Recurrence, Treatment Outcome

ID: 44728211